June 2026 in “Dermatology and Therapy” In this retrospective analysis, patients with trichodynia who were unresponsive to standard treatments showed significant symptom improvement after receiving intradermal botulinum toxin type A, with nearly all patients benefiting, particularly those with scarring alopecia.
This study found that subcutaneous administration of Botulinum toxin type A significantly reduced histamine-induced itch intensity and neurogenic inflammation in human skin compared to saline.
3 citations
,
January 2022 in “Neurotoxicity Research” This study found that botulinum toxin type A injections in stressed mice appeared to normalize hair follicle regeneration cycles and reduced stress-related hair loss indicators.
April 2024 in “Skin research and technology” This study suggests that while subcutaneous Botulinum Toxin Type A may offer short-term symptom improvement for female pattern hair loss, its effectiveness does not extend beyond three months.
53 citations
,
January 2017 in “Skin appendage disorders” This review discusses botulinum toxin's experimental off-label uses in dermatology, highlighting promising results but emphasizing the need for more clinical trials to confirm efficacy and safety.